Biorestorative Therapies Reports Q4 Loss, Lags Revenue Estimates

Biorestorative Therapies reported a Q4 loss of $0.32 per share, beating the Zacks Consensus Estimate of a loss of $0.37, but missing revenue estimates by 90.2%. The company has underperformed the market this year, with shares down 73.6%. The earnings outlook is mixed, with a Zacks Rank of #3 (Hold) indicating expected performance in line with the market. The current consensus EPS estimate is -$0.49 on $0.25 million in revenues for the coming quarter and -$1.17 on $1.3 million in revenues for the current fiscal year.